Stockscreener 앱 받기
19.61
1.24%
0.24
시간 외 거래:
19.61
전일 마감가:
$19.37
열려 있는:
$19.39
하루 거래량:
544.30K
Relative Volume:
0.67
시가총액:
$1.13B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-8.8333
EPS:
-2.22
순현금흐름:
$-105.32M
1주 성능:
-2.53%
1개월 성능:
+7.81%
6개월 성능:
-17.48%
1년 성능:
-49.91%
1일 변동 폭
$19.19
$19.88
1주일 범위
$18.39
$21.44
52주 변동 폭
$13.22
$45.37
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(628) 229-9277
주소
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
GPCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
19.61 | 1.15B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-02 | 개시 | Citigroup | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-12-04 | 개시 | H.C. Wainwright | Buy |
| 2024-09-23 | 개시 | Morgan Stanley | Overweight |
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Wall Street Analysts Are Neutral on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protara Therapeutics (TARA), Annexon Biosciences (ANNX) and Agilent (A) - The Globe and Mail
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform - MarketScreener
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors - The Motley Fool
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire
Structure Therapeutics’ SWOT analysis: oral GLP-1 stock faces pivotal phase - Investing.com
SEED Therapeutics Named Finalist for 2025 Prix Galien USA 'Best Start-Up” Award - The Manila Times
Can Structure Therapeutics’ (GPCR) Aggressive Funding Moves Accelerate Its Obesity Drug Ambitions? - Yahoo Finance
ABSSSI Pipeline 2025: Detailed Clinical Trials - openPR.com
Up 23% to 132%, There's Still Time to Buy These 3 Stocks - The Globe and Mail
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
FY2025 EPS Estimates for GPCR Lowered by Cantor Fitzgerald - Defense World
William Blair Has Bearish Forecast for GPCR Q3 Earnings - Defense World
FY2025 EPS Estimates for GPCR Decreased by HC Wainwright - Defense World
Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings - Defense World
Leerink Partnrs Issues Negative Outlook for GPCR Earnings - Defense World
PepGen Inc.’s Promising Clinical Developments and Strategic Advancements Earn a Buy Rating - TipRanks
Why Is Everyone Talking About UnitedHealth Group Stock? - The Globe and Mail
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors - AOL.com
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
High demand expected for new daily weight loss pill - inkl
Structure Therapeutics (GPCR) to Release Quarterly Earnings on Thursday - Defense World
Structure Therapeutics Reports Q2 2025 Financial Results - TipRanks
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights - The Manila Times
The GLP-1 Arms Race: Emerging Innovators and Capital Efficiency in the Obesity Drug Gold Rush - AInvest
Structure Therapeutics Inc ADR (GPCR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Layoff Tracker: Sirona Liquidates TFChem, Merck Will Cut 6,000 Employees - BioSpace
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Chefs’ Warehouse (NASDAQ:CHEF) Reaches New 52-Week High After Better-Than-Expected Earnings - Defense World
Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17 - Defense World
Brookfield (NYSE:BN) Upgraded at National Bank Financial - Defense World
Camden National (NASDAQ:CAC) Stock Price Down 7.6% Following Weak Earnings - Defense World
Century Lithium (OTC:CYDVF) Shares Down 2.6% – What’s Next? - Defense World
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 0.9% – Here’s What Happened - Defense World
HCM Acquisition (NASDAQ:HCMA) Stock Price Down 3.4% – Here’s Why - Defense World
DeFi Technologies (OTC:DEFTF) Trading 20% Higher – What’s Next? - Defense World
GCM Grosvenor (NASDAQ:GCMGW) Trading Up 1.1% – Should You Buy? - Defense World
Encore Capital Group (NASDAQ:ECPG) & Manhattan Bridge Capital (NASDAQ:LOAN) Critical Review - Defense World
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioNTech SE (BNTX) and Galapagos (GLPG) - The Globe and Mail
Obesity Clinical Trials, Companies, Therapeutic Assessment, - openPR.com
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Private Advisor Group LLC Buys 489 Shares of Quanta Services, Inc. (NYSE:PWR) - Defense World
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN) - The Globe and Mail
Easterly Investment Partners LLC Has $23.78 Million Stock Position in JPMorgan Chase & Co. (NYSE:JPM) - Defense World
Microchip Technology Incorporated (NASDAQ:MCHP) Holdings Decreased by Private Advisor Group LLC - Defense World
Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Shilanski & Associates Inc. - Defense World
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):